Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia.

ABSTRACT:

Background

Vimentin (VIM) is a type III intermediate filament that maintains cell integrity, and is involved in cell migration, motility and adhesion. When overexpressed in solid cancers, vimentin drives epithelial to mesenchymal transition (EMT) and ultimately, metastasis. The effects of its overexpression in AML are unclear.

Methods

In this study, we analyzed the TCGA data of 173 AML patients for which complete clinical and expression data were available. In this analysis, we assessed the association between VIM mRNA expression and patient's clinical and molecular characteristics including clinical outcome.

Results

VIM overexpression was associated with higher white blood count (< p = 0.0001). Patients with high VIM expression have worse overall survival (OS) and di

SUBMITTER: Wu S 

PROVIDER: S-EPMC6009962 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature